Forefront Wealth Partners, LLC Cytom X Therapeutics, Inc. Transaction History
Forefront Wealth Partners, LLC
- $397 Billion
- Q3 2025
A detailed history of Forefront Wealth Partners, LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Forefront Wealth Partners, LLC holds 18,109 shares of CTMX stock, worth $69,900. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,109Holding current value
$69,900% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
106Shares Held
117MCall Options Held
1.5MPut Options Held
321K-
Vr Adviser, LLC New York, NY15.6MShares$60.1 Million7.54% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$42.7 Million1.6% of portfolio
-
Perceptive Advisors LLC New York, NY9.68MShares$37.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$34.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$32.7 Million0.92% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $255M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...